Use of Dupilumab to Manage Antibody-Drug Conjugate–Induced Cutaneous Toxicities

Ian Nykaza(Memorial Sloan Kettering Cancer Center), Allison Gordon(Memorial Sloan Kettering Cancer Center), Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Emily Feld(Memorial Sloan Kettering Cancer Center), Alina Markova(National Technical University "Kharkiv Polytechnic Institute"), Gopa Iyer(Memorial Sloan Kettering Cancer Center), Stephen W. Dusza(Memorial Sloan Kettering Cancer Center), Megan Bielawa(Memorial Sloan Kettering Cancer Center), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Devika Gajria(Memorial Sloan Kettering Cancer Center)
JAMA Dermatology
July 30, 2025
10.1001/jamadermatol.2025.2567
Cited by 1

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Skin Lesion Analysis Toward Melanoma Detection 2018: A Challenge Hosted by the International Skin Imaging Collaboration (ISIC)
|arXiv (Cornell University)|2019|990
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|572
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
|Oncogene|2016|430